The U.S. Food and Drug Administration approved French drugmaker Sanofi's hemophilia therapy, introducing a new type of ...

Could your heavy flow be cause for concern? Sherri Ozawa, MSN, RN, tells The Post that serious blood loss during menstruation ...

The City of College Station issued a proclamation just in time for National Bleeding Disorders Awareness Month.

WASHINGTON: The US Food and Drug Administration (FDA) approved French drugmaker Sanofi’s haemophilia therapy, paving the way for a new type of treatment for patients with the rare blood clotting ...

Hematohidrosis, or Haematidrosis, is a rare condition where a person sweats blood instead of normal perspiration. The ...

These sentiments resonated as members of Sangre de Oro, the Bleeding Disorder Foundation of New Mexico, gathered for Family Education Weekend March 21-23 in Albuquerque. While many chapters around the ...

Sanofi’s subcutaneous, or under-the-skin, therapy helps prevent bleeding and lowers antithrombin, a protein that delays blood clotting, for haemophilia patients aged 12 years and older.

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

Data from the ATLAS research comprises a series of trials that have yielded years of long-term, comprehensive data on safety ...

A recent gathering of the New Mexico bleeding disorders community provided many opportunities for support, columnist Joe MacDonald says.